EUVIMEDEUVIMED entdecken
Crossref

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines

Daisuke Ide, Hidetomo Yokoo, Shinsuke Mizutani, Yu Inoue, Haruya Okamoto, Taku Tsukamoto, Yosuke Demizu, Yuji Shimura, Makoto Oba, Junya Kuroda

Chemical and Pharmaceutical Bulletin · 18.03.2026 · 74 (3) · 240-246

DOI: 10.1248/cpb.c25-00731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, erschienen am 18.03.2026. Verfasst von Daisuke Ide und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-cho, Sakyo-ku, …. Hauptthemen laut MEDLINE: Multiple Myeloma, Ribosomal Protein S6 Kinases, 90-kDa, Antineoplastic Agents, Thalidomide. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaRibosomal Protein S6 Kinases, 90-kDaAntineoplastic AgentsThalidomideProtein Kinase InhibitorsHumansProteolysisCell Line, TumorMolecular Docking SimulationCell ProliferationProteolysis Targeting ChimeraStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

multiple myelomaproteolysis targeting chimeraribosomal S6 kinase 2ribosomal S6 kinase inhibitor

Substanzen

Ribosomal Protein S6 Kinases, 90-kDaribosomal protein S6 kinase, 90kDa, polypeptide 3Antineoplastic AgentsThalidomideProteolysis Targeting ChimeraProtein Kinase Inhibitorspomalidomide

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-cho, Sakyo-ku, Kyoto 606-0823, Japan.
  • Medical Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
  • National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Japan.

Zitieren

APA

Ide, D., Yokoo, H., Mizutani, S., Inoue, Y., Okamoto, H., Tsukamoto, T., Demizu, Y., Shimura, Y., Oba, M., & Kuroda, J. (2026). Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines. Chemical and Pharmaceutical Bulletin, 74(3), 240-246. https://doi.org/10.1248/cpb.c25-00731

Vancouver

Ide D, Yokoo H, Mizutani S, Inoue Y, Okamoto H, Tsukamoto T, et al. Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines. Chemical and Pharmaceutical Bulletin. 2026;74(3):240-246. doi:10.1248/cpb.c25-00731

BibTeX
@article{Ide2026,
  author = {Ide, Daisuke and Yokoo, Hidetomo and Mizutani, Shinsuke and Inoue, Yu and Okamoto, Haruya and Tsukamoto, Taku and Demizu, Yosuke and Shimura, Yuji and Oba, Makoto and Kuroda, Junya},
  title = {Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines},
  journal = {Chemical and Pharmaceutical Bulletin},
  year = {2026},
  volume = {74},
  number = {3},
  pages = {240--246},
  doi = {10.1248/cpb.c25-00731}
}
Kostenlos starten →